Abcellera Biologics Inc (ABCL)

$3.69 +0.07 (1.93%)
Market Cap 1.08B
Revenue (ttm) 28.83M
Net Income (ttm) -162.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -564.90%
Debt to Equity Ratio 0.00
Volume 4,257,700
Avg Vol 5,401,348
Day's Range N/A - N/A
Shares Out 299.34M
Stochastic %K 15%
Beta 0.70
Analysts Strong Sell
Price Target $9.14

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research coll...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 West 4th Ave, Vancouver, Canada
Stocktradesmoon
Stocktradesmoon Nov. 15 at 3:14 AM
$ABCL That’s 10X their original position what must they know hmmm 🧐
0 · Reply
mxli_5811
mxli_5811 Nov. 15 at 3:01 AM
$ABCL
0 · Reply
estatebuyersmia
estatebuyersmia Nov. 15 at 1:15 AM
$ABCL SAYS IT ALL
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 14 at 9:49 PM
💎 LiquidTheta® Live Actionable Trade Asset: $ABCL Contracts: $ABCL January 15, 2027 $4 Calls Scale in: $1.32- $1.61 Scale out: $5.12-$8.77 Profit Potential : 121% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
estatebuyersmia
estatebuyersmia Nov. 14 at 9:24 PM
$ABCL FOR ED NG AND ANYONE ELSE WHO DOUBTS...
1 · Reply
estatebuyersmia
estatebuyersmia Nov. 14 at 8:22 PM
$ABCL READ
0 · Reply
Ckkung71
Ckkung71 Nov. 14 at 8:05 PM
$ABCL 1. The phase 2 will be finish around q1 2026. 2. The closer a biotech company is to a breakthrough the more easily the will find investors. 3. They business partners increase every quarter.
1 · Reply
estatebuyersmia
estatebuyersmia Nov. 14 at 7:03 PM
$ABCL READ THIS...
1 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 6:21 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ABCL $3.00 Put · NOV 21, 2025 Exp Entry Price: $0.15 - $0.15 Exit Price Target: $0.30 Profit Margin: +97% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
JG101
JG101 Nov. 14 at 4:53 PM
$ABCL The drop yesterday was probably secondary to the market realizing the nearest commercialization prospect for their most advanced antibody is in 5 years (the CFO specifically said this) and a lot of things can go wrong. They have a lot of money but will likely burn through it all before commercializations. Having over a billion in market cap for an early phase 1 asset is generous at best. Anyone who doubts this could retest the 2.xx per share is delusional. It would be a good buying opportunity but even at 2$ a share in a year or 2 the company isn’t cheap if the cash pile is meaningfully spent…
4 · Reply
Latest News on ABCL
AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 4 days ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 7:16 PM EST - 7 days ago

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 8 days ago

AbCellera Reports Q3 2025 Business Results

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 7, 2025, 4:05 PM EDT - 5 weeks ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

AbCellera Biologics: Entering Growth Phase After A Pause

Oct 6, 2025, 7:35 AM EDT - 5 weeks ago

AbCellera Biologics: Entering Growth Phase After A Pause

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 29, 2025, 4:05 PM EDT - 6 weeks ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 2 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 27, 2025, 9:00 AM EDT - 2 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 12, 2025, 4:05 PM EDT - 3 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:48 PM EDT - 3 months ago

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 7, 2025, 4:05 PM EDT - 3 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 7, 2025, 4:05 PM EDT - 4 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 30, 2025, 1:00 PM EDT - 6 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 14, 2025, 5:00 PM EDT - 6 months ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 12, 2025, 3:30 PM EDT - 6 months ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 9, 2025, 7:30 PM EDT - 6 months ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

May 8, 2025, 10:33 PM EDT - 6 months ago

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 6 months ago

AbCellera Reports Q1 2025 Business Results

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 3:00 PM EDT - 7 months ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 8, 2025, 4:05 PM EDT - 7 months ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 3, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 25, 2025, 4:30 PM EDT - 8 months ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 11:26 PM EST - 9 months ago

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 9 months ago

AbCellera Reports Full Year 2024 Business Results

AbCellera to Participate at Upcoming Investor Conferences in March

Feb 11, 2025, 4:05 PM EST - 9 months ago

AbCellera to Participate at Upcoming Investor Conferences in March

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 21, 2025, 4:05 PM EST - 10 months ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Jan 13, 2025, 9:00 AM EST - 10 months ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera Biologics: Still A Concept Stock

Dec 23, 2024, 4:39 PM EST - 11 months ago

AbCellera Biologics: Still A Concept Stock

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 7:22 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

AbCellera: A Platform To Pipeline Transition

Oct 14, 2024, 12:04 PM EDT - 1 year ago

AbCellera: A Platform To Pipeline Transition

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

AbCellera to Present at Upcoming Investor Conferences in September

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

AbCellera: A Waiting Game With High Uncertainty

Aug 23, 2024, 4:43 AM EDT - 1 year ago

AbCellera: A Waiting Game With High Uncertainty

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 25, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 28, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript

May 7, 2024, 11:00 PM EDT - 1 year ago

AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript

AbCellera Reports Q1 2024 Business Results

May 7, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2024 Business Results

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

May 1, 2024, 9:00 AM EDT - 1 year ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Apr 8, 2024, 12:05 PM EDT - 1 year ago

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

Apr 3, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

Mar 19, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

Mar 11, 2024, 9:00 AM EDT - 1 year ago

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

BIIB

Stocktradesmoon
Stocktradesmoon Nov. 15 at 3:14 AM
$ABCL That’s 10X their original position what must they know hmmm 🧐
0 · Reply
mxli_5811
mxli_5811 Nov. 15 at 3:01 AM
$ABCL
0 · Reply
estatebuyersmia
estatebuyersmia Nov. 15 at 1:15 AM
$ABCL SAYS IT ALL
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 14 at 9:49 PM
💎 LiquidTheta® Live Actionable Trade Asset: $ABCL Contracts: $ABCL January 15, 2027 $4 Calls Scale in: $1.32- $1.61 Scale out: $5.12-$8.77 Profit Potential : 121% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
estatebuyersmia
estatebuyersmia Nov. 14 at 9:24 PM
$ABCL FOR ED NG AND ANYONE ELSE WHO DOUBTS...
1 · Reply
estatebuyersmia
estatebuyersmia Nov. 14 at 8:22 PM
$ABCL READ
0 · Reply
Ckkung71
Ckkung71 Nov. 14 at 8:05 PM
$ABCL 1. The phase 2 will be finish around q1 2026. 2. The closer a biotech company is to a breakthrough the more easily the will find investors. 3. They business partners increase every quarter.
1 · Reply
estatebuyersmia
estatebuyersmia Nov. 14 at 7:03 PM
$ABCL READ THIS...
1 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 6:21 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ABCL $3.00 Put · NOV 21, 2025 Exp Entry Price: $0.15 - $0.15 Exit Price Target: $0.30 Profit Margin: +97% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
JG101
JG101 Nov. 14 at 4:53 PM
$ABCL The drop yesterday was probably secondary to the market realizing the nearest commercialization prospect for their most advanced antibody is in 5 years (the CFO specifically said this) and a lot of things can go wrong. They have a lot of money but will likely burn through it all before commercializations. Having over a billion in market cap for an early phase 1 asset is generous at best. Anyone who doubts this could retest the 2.xx per share is delusional. It would be a good buying opportunity but even at 2$ a share in a year or 2 the company isn’t cheap if the cash pile is meaningfully spent…
4 · Reply
Ed_Ng
Ed_Ng Nov. 14 at 4:46 PM
$ABCL still in profit. You still have mindset of penny boy ;-)
0 · Reply
estatebuyersmia
estatebuyersmia Nov. 14 at 4:36 PM
$ABCL CAN YOU SAY PROFIT.... Hello ED NG
0 · Reply
Ed_Ng
Ed_Ng Nov. 14 at 3:22 PM
$ABCL ? You bought at 4$. You are dead! I shorted at 5 and 6, I'm money maker
1 · Reply
estatebuyersmia
estatebuyersmia Nov. 14 at 2:59 PM
$ABCL IAM MAKING MONEY ED... DID YOU COVER YET?
0 · Reply
Ed_Ng
Ed_Ng Nov. 14 at 2:09 PM
$ABCL and they have nothing in the market rather than theory and money burn.
1 · Reply
Ed_Ng
Ed_Ng Nov. 14 at 2:09 PM
$ABCL 3$ today. 2$ in DEC.
0 · Reply
estatebuyersmia
estatebuyersmia Nov. 14 at 12:39 PM
$ABCL READ
0 · Reply
Stocktradesmoon
Stocktradesmoon Nov. 14 at 12:26 PM
$ABCL Added with you
1 · Reply
estatebuyersmia
estatebuyersmia Nov. 14 at 12:24 PM
$ABCL You have to realize there is no reason for this sell off, no failed pipeline, no earnings disaster, nothing negative... Everything is still intact...
1 · Reply
estatebuyersmia
estatebuyersmia Nov. 14 at 12:19 PM
$ABCL rebound will be sharp, violent...
0 · Reply
estatebuyersmia
estatebuyersmia Nov. 14 at 12:19 PM
$ABCL selling is overdone, premarket volume very light... Most likely weak holders... Rebound coming, trust me on this...
0 · Reply
estatebuyersmia
estatebuyersmia Nov. 14 at 12:13 PM
$ABCL added more this morning..
0 · Reply